GUTS$0.9014-4.37%
Fractyl Health, Inc.
Sector: Surgical & Medical Instruments & ApparatusIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$11.96M
Float & O/S:
Inst Own:
DilutionScan read 29 of FRACTYL HEALTH, INC.'s SEC filings and found 6 warrant series, 1 convertible, 1 ATM program, 1 shelf registration, 1 S-1 registration and 3 completed offerings on file for GUTS. The latest dilution event on file is ATM sales on Apr 6, 2026. Analysis updated Oct 14, 2026.
Signal8 Summary
GUTS
Going-concern-level cash crunch despite trial win
- Business
- WeakNo revenue, $141M net loss, 5.3-month runway
- Stock risk
- HighMicro-cap, fresh reverse split, shares +252% YoY
Snapshot
Fractyl Health is a pre-revenue biotech developing a procedural therapy for diabetes and obesity. FY 2025 revenue was $0, with a $141.0M net loss and $90.3M burned from operations.
What's Happening Right Now
- : Fractyl's REMAIN-1 pivotal study hit its six-month weight-regain endpoint with strong statistical significance, and the company now plans an FDA De Novo filing in late Q4 2026, targeting a possible 2028 launch.
- : Sell-side coverage settled on a consensus 'Hold' rating, made up of one sell, one hold, and three buy recommendations.
- : Fractyl completed a 1-for-12 reverse stock split effective Oct 2, 2026, a move typically used to stay compliant with Nasdaq's minimum share price rule.
- : On Sep 24, 2026, stockholders approved giving the board discretion to set the reverse-split ratio anywhere from 1-for-5 to 1-for-15.
- : Sold $22K net through its at-the-market program.
- : Sold $6.78M net / 392K shares through its at-the-market program, as stated for Jan 1, 2025 to Dec 31, 2025.
- : Issued warrants.
